Unicar-Therapy
Latest round
- Series B
Last raised
- Mar 2021
Total raised
- Undisclosed
Investors
- 5
About Unicar-Therapy
Established in 2015 and based in Shanghai, China, Unicar-Therapy is a biotechnology company that focuses on the development of CAR-T and other cell/gene therapy technologies and products. Unicar-Therapy has won many honors, such as the China Cell Therapy Enterprise Rapid Growth Award, the 2019 Future Medical Top 100 - Top 100 China Innovative Medicine List, and the 2020 Top 100 Chinese Pharmaceutical Innovation Enterprises. Unicar-Therapy cooperated with Hainan Haiyao to build a gene and cell therapy center in Hainan. The company is committed to the development of CAR-T and other cell/gene therapy products. It uses CAR-T therapy, builds antibody screening platforms and GMP production bases to develop CAR-T products for tumor treatment, and has completed more than 1,000 CAR-T clinical studies and treatments with the hematology departments of many domestic hospitals.0 product, SSCART-19 injection, in a formal clinical trial.
Who invested in Unicar-Therapy
5 investors across 3 rounds
See all investors in Unicar-Therapy
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Unicar-Therapy
Who invested in Unicar-Therapy?
Unicar-Therapy has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Unicar-Therapy raised?
Unicar-Therapy has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Unicar-Therapy last raise money?
Unicar-Therapy's most recent round on record is a Series B, in Mar 2021.
What does Unicar-Therapy do?
Established in 2015 and based in Shanghai, China, Unicar-Therapy is a biotechnology company that focuses on the development of CAR-T and other cell/gene therapy technologies and products.
Where is Unicar-Therapy headquartered?
Unicar-Therapy is headquartered in Shanghai, China.
Which VCs invest in companies like Unicar-Therapy?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Unicar-Therapy's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Unicar-Therapy? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.